27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
The 2017 ESMO Congress wraps up on Tuesday in Madrid, Spain. On Monday, Jefferies issued a handful of flash notes related to companies presenting at the conference.
Here’s a breakdown of the highlights.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Five Prime Therapeutics
Five Prime Therapeutics Inc (NASDAQ:FPRX) reported positive data on its Phase I trials of FP-1039 in treatment of mesothelioma.
“Currently we do not include FP-1039 in our valuation; thus, if successfully developed, it would provide upside,” analyst Eun Yang wrote.
Bristol-Myers Squibb
Analyst Jeffrey Holford said new data on Bristol-Myers Squibb Co (NYSE:BMY)’s CM-214 suggests the market is prematurely writing off Yervoy.
“We see the CM-214 data driving a new indication and growth for Yervoy, helping to support our above consensus 2021E revenue estimate of $3.1bn vs. consensus of $1.8bn,” Holford wrote.
Eli Lilly
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Holford said early indications suggest Eli Lilly and Co (NYSE:LLY) breast cancer treatment drug Abema could be the best in its class in terms of efficacy, but more data will be needed to support the initial findings.
“We see room for upside against our own and consensus estimates for Abema and have previously estimated that this could increase mid-term EPS and valuation for LLY by c3%-5%,” he wrote.
Related Link: What Pharmaceuticals Spend On Lobbying To Influence Trump
Array Biopharma
Array Biopharma Inc (NASDAQ:ARRY) reported some positive safety data from its ongoing Phase III BEACON trial. Yang said the new data suggests major potential for Array’s melanoma combination treatment.
“Aside from potential bini/enco approval by ~mid-2018 in somewhat crowded melanoma market, its combo potential in unmet CRC indication with limited competition & ~$1B market size represents likely upside, if successful,” Yang wrote.
Price Targets And Ratings
Jefferies maintains the following ratings and price targets on the four stocks mentioned above:
- Five Prime—Buy rating, $52 price target
- Bristol Myers—Buy rating, $66 price target
- Eli Lilly—Buy rating, $89 price target
- Array Biopharma—Buy rating, $9 price target
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.